🇺🇸 FDA
Patent

US 11718612

Inhibitors of receptor interacting protein kinase I for the treatment of disease

granted A61KA61K31/4035A61K31/407

Quick answer

US patent 11718612 (Inhibitors of receptor interacting protein kinase I for the treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/4035, A61K31/407, A61K31/415, A61K31/4172